Physician profile
Lori S Hopper
NPI 1396033619
$1,943.96
in general payments reported to CMS, 2019-2025
26 companies · $520 in 2025
The $520 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $254 · 2023: $83.74 · 2024: $963 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $240.43 | 2024-2025 | Krystexxa, Evenity, Prolia |
| Abbvie INC. | $230.50 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $213.89 | 2023-2025 | Austedo Xr, Austedo Xr |
| Impulse Dynamics (USA) INC. | $154.53 | 2022 | |
| Janssen Biotech, INC. | $150.88 | 2024-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $124.96 | 2024-2025 | Bimzelx, Rystiggo |
| Lundbeck LLC | $116.04 | 2024 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $111.95 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $99.05 | 2022-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $65.50 | 2024-2025 | |
| Genentech USA, INC. | $64.29 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Eisai INC. | $63.77 | 2024 | |
| Tg Therapeutics, INC. | $43.34 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $33.79 | 2025 | Airsupra |
| Lilly USA, LLC | $29.31 | 2022-2024 | Mounjaro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $27.68 | 2024 | Injectafer |
| Genzyme Corporation | $24.36 | 2025 | |
| Glaxosmithkline, LLC. | $21.31 | 2024 | Benlysta |
| Xeris Pharmaceuticals, INC. | $20.31 | 2022 | |
| Nevro Corp. | $19.80 | 2024 | Senza |
| Regeneron Healthcare Solutions, INC. | $18.25 | 2025 | Dupixent |
| Antares Pharma, INC. | $16.19 | 2024 | Xyosted |
| Mayne Pharma Commercial LLC | $14.82 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.35 | 2021 | |
| Vistapharm, INC. | $13.00 | 2021 | |
| Currax Pharmaceuticals LLC | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Hopper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.